"Effects of Rigid Tape in Patients With Chronic Achilles Tendinopathy"

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Gran Rosario

About this trial

The aim of this study will be to determine the clinical effects of rigid tape in patients with chronic MAT. The secondary outcomes will be to evaluate the immediate and short term pain, the height and pain during the vertical jump, the satisfaction of the use of the tape and the global rating of change (GROC) of the intervention. This study will be a double-blinded randomized clinical trial comprising a total sample size of 36 participants with MAT of both genders and aged between 18 and 50 years. Subjects will undergo a screening process by a sports medicine doctor by different diagnostic tests to identify those presenting a diagnosis of painful MAT and then, they will be randomized into either a group performing experimental rigid tape (G1), or a group performing placebo tape (G2). The study will assess the subjects immediate and short-term tendon pain following the tape application during running and vertical jump. Also the tape satisfaction and GROC will be assessed. The rigid tape will be applied in the central portion of the Achilles tendon. Primary and secondary outcomes will be measured at baseline, immediate after the application of the tape and 72 hours after. The GROC will only be assessed at the end of the treatment. All the evaluations will be performed by a blinded physiotherapist. The patient will also be blinded.

Eligibility criteria

Qualifiers

Clinical diagnosis of unilateral or bilateral MAT

Achilles pain > 3 months

Age ranging between 18 to 50 years, both genders

Read and speak Spanish well enough to provide informed consent and follow study instructions.

Disqualifiers

Any ankle or foot surgery

History of Achilles rupture

Heel pain in the last 3 months

Systemic disorders/diseases

Trial design

Treatments tested in this trial

  • Rigid Tape
  • Placebo Control

Treatment groups

36 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators